Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 10:7. Implied volatility suggests the market is anticipating a move near 14.9%, or 41c, after results are released. Median move over the past eight quarters is 2.6%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio Releases Video on Alzheimer’s Trial Results
- Largest borrow rate increases among liquid names
- INmune Bio announces video detailing findings from Phase 2 MINDFuL trial
- Inmune Bio Reveals Promising XPro™ Trial Results
- INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met